Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Accenture
Cerilliant
US Department of Justice
Queensland Health
Johnson and Johnson
McKesson
Cantor Fitzgerald
Novartis
Covington

Generated: October 18, 2017

DrugPatentWatch Database Preview

Braintree Company Profile

« Back to Dashboard

What is the competitive landscape for BRAINTREE, and when can generic versions of BRAINTREE drugs launch?

BRAINTREE has six approved drugs.

There are three US patents protecting BRAINTREE drugs.

There are twenty patent family members on BRAINTREE drugs in thirteen countries and thirteen supplementary protection certificates in eight countries.

Summary for Applicant: Braintree

International Patents:20
US Patents:3
Tradenames:7
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree Labs
SUCLEAR
magnesium sulfate; polyethylene glycol 3350; potassium chloride; potassium sulfate; sodium bicarbonate; sodium chloride; sodium sulfate
SOLUTION;ORAL203595-001Jan 18, 2013DISCNYesNo► Subscribe► Subscribe► Subscribe
Braintree
GOLYTELY
polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous
FOR SOLUTION;ORAL019011-001Jul 13, 1984AARXYesYes► Subscribe► Subscribe► Subscribe
Braintree
NULYTELY-FLAVORED
polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
FOR SOLUTION;ORAL019797-002Nov 18, 1994AARXYesYes► Subscribe► Subscribe► Subscribe
Braintree Labs
SUPREP BOWEL PREP KIT
magnesium sulfate; potassium sulfate; sodium sulfate
SOLUTION;ORAL022372-001Aug 5, 2010AARXYesYes► Subscribe► SubscribeY ► Subscribe
Braintree
HALFLYTELY
bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL021551-003Jul 16, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Braintree
AXID
nizatidine
SOLUTION;ORAL021494-001May 25, 2004DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Braintree
GOLYTELY
polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous
FOR SOLUTION;ORAL019011-002Jun 2, 1992RXYesYes► Subscribe► Subscribe► Subscribe
Braintree
NULYTELY
polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
FOR SOLUTION;ORAL019797-001Apr 22, 1991AARXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRAINTREE drugs

Drugname Dosage Strength Tradename Submissiondate
sodium sulfate, potassium sulfate and magnesium sulfate
Oral Solution17.5 g/3.13 g/1.6 g per bottle
SUPREP BOWEL PREP KIT
11/8/2010
polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl
For Oral Solution and Delayed-release Tablet210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen)
HALFLYTELY
7/30/2010
nizatidine
Oral Solution15 mg/mL
AXID
5/14/2008
polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl
For Oral Solution and Delayed-210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg
HALFLYTELY
1/28/2008

International Patent Family for Braintree Drugs

Country Document Number Estimated Expiration
Cyprus1112522► Subscribe
Portugal2292244► Subscribe
Denmark2292244► Subscribe
Spain2441890► Subscribe
World Intellectual Property Organization (WIPO)2004009077► Subscribe
European Patent Office2233147► Subscribe
Denmark2233147► Subscribe
Germany60331220► Subscribe
Slovenia1499331► Subscribe
European Patent Office2292244► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Braintree Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0483Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
90006-4Sweden► SubscribePRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812
C/GB01/006United Kingdom► SubscribePRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
2012000017Germany► SubscribePRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
00483Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
00517Netherlands► SubscribePRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812
00615Netherlands► SubscribePRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
0130010 00080Estonia► SubscribePRODUCT NAME: NAATRIUMSULFAAT, MAGNEESIUMSULFAATHEPTAHUEDRAAT JA;REG NO/DATE: RR-4/5 04.03.2013
00482Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
2012 00035Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Moodys
Harvard Business School
Daiichi Sankyo
Farmers Insurance
Cipla
Johnson and Johnson
Federal Trade Commission
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot